Webinar | TiO₂ alternatives for food, pharma, and personal care Register Here

ResBiotic

ResBiotic develops probiotic and pharmabiotic therapies to alleviate neutrophilic inflammation associated with dysbiosis.
2018
11-50
Vestavia Hills, Alabama, United States
BiopharmaBiotechnologynologyPre & ProbioticsTherapeutics

Investment Funding

Last Funding Stage

Undisclosed

Total Funding Amount

7.14M

Last Funding Amount

1.5M

Last Funding Date

26-02-2025

Lead Investors

Timberline Investments

Revenue

$1M to $10M

People

Founders